Target type: biologicalprocess
Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving dopamine. [GOC:go_curators]
Negative regulation of dopamine metabolic process refers to the biological mechanisms that decrease the rate or extent of dopamine metabolism. Dopamine metabolism is the breakdown of dopamine, a neurotransmitter crucial for various physiological processes, including movement, motivation, and reward. This process is tightly regulated to ensure proper dopamine levels within the nervous system.
The negative regulation of dopamine metabolic process involves several molecular players and pathways. One key mechanism is the inhibition of enzymes responsible for dopamine catabolism. These enzymes, such as monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT), break down dopamine into inactive metabolites.
Several factors can influence this regulation. For instance, specific neurotransmitters like acetylcholine can inhibit MAO activity. Additionally, certain medications like MAO inhibitors are used to treat conditions like depression by blocking MAO activity and increasing dopamine levels.
Moreover, the expression and activity of these catabolic enzymes can be regulated at the gene level. Transcription factors and signaling pathways can modulate the expression of genes encoding MAO and COMT, thereby affecting dopamine metabolism.
Furthermore, the negative regulation can occur via the modulation of dopamine reuptake. Dopamine transporters (DAT) are responsible for removing dopamine from the synaptic cleft, terminating its signaling. Inhibiting DAT activity can prolong dopamine's action, indirectly leading to a decrease in dopamine metabolism.
Overall, the negative regulation of dopamine metabolic process is a complex process involving multiple mechanisms, including enzymatic inhibition, gene expression regulation, and transporter modulation. This intricate regulation ensures appropriate dopamine levels in the brain, contributing to normal physiological functioning.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| Integrin beta-2 | An integrin beta-2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P05107] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| indole | indole; polycyclic heteroarene | Escherichia coli metabolite | |
| 1,4-benzodioxan | 1,4-benzodioxan: structure in first source | ||
| 1-methylindole | 1-methylindole: SKATOLE refers to 3-methylindole; RN given refers to parent cpd; structure methylindole : Any member of the class of indoles carrying one or more methyl substituents. | ||
| lovastatin | lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom). Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver. | delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring) | anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug |
| chlorfenethazine | chlorfenethazine: RN given refers to parent cpd; synonym elroquil refers to HCl; structure | phenothiazines | |
| 2-bromohippuric acid | |||
| benzotript | benzotript: anti-gastrinic; active group is amide; structure | ||
| birt 377 | |||
| a 286982 | A 286982: inhibits the interaction between leukocyte function-associated antigen-1 and intracellular adhesion molecule-1; structure in first source | ||
| bio 1211 | BIO 1211: integrin alpha4beta1 inhibitor; structure in first source | ||
| sar 1118 | lifitegrast : An N-acyl-L-alpha-amino acid obtained by formal condensation of the carboxy group of N-[2-(1-benzofuran-6-carbonyl)]-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid with the amino group of 3-(methanesulfonyl)-L-phenylalanine. Used for treatment of keratoconjunctivitis sicca (dry eye syndrome). lifitegrast: An LFA-1 (LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1) antagonist that is used in the treatment of DRY EYE SYNDROMES. | 1-benzofurans; isoquinolines; L-phenylalanine derivative; N-acyl-L-alpha-amino acid; sulfone | anti-inflammatory drug; lymphocyte function-associated antigen-1 antagonist |